The tweet was deleted by the author.
But we saved everything 🙂.
Agenus presented new three-year follow-up data from its Phase 1b trial of BOT plus BAL in patients with recurrent ovarian cancer. The estimated overall survival was 48 percent at three years, which remains unchanged from the two-year estimate in a heavily pretreated patient population.
The findings were shared at IGCSociety’s IGC2026 conference, providing updated insights into the potential long-term outcomes of the treatment protocol.
View post on X Loading...
Agenus previously disclosed new details on the execution of its ROBBIN Phase 3 program and its BOT+BAL immunotherapy strategy in colorectal cancer in an earlier update. The company also presented long-term survivor and translational research findings on BOT plus BAL in colorectal cancer at SITC2026, as reported in another recent announcement. These prior reports focused on colorectal cancer, while the latest data addresses recurrent ovarian cancer outcomes.